|Articles|April 4, 2023
Calyx Announces Partnership With Ceretype Neuromedicine
Advertisement
Calyx has announced a strategic partnership with Ceretype Neuromedicine, Inc., whose novel functional MRI (fMRI) platform incorporates optimal image acquisition and advanced analytics to de-risk and accelerate the development of psychiatric and neurological therapies.
The Ceretype platform utilizes fMRI and artificial intelligence to connect neural circuitry to patient behaviors and treatment outcomes, delivering the objective biologic endpoints for more precise measurement of treatment effects during central nervous system drug development.
Reference
Calyx Delivers Imaging Biomarkers to Advance Neuropsychiatric Treatment Development. (2023, April 4). Cision PR Newswire.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
2
Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work
3
ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment
4
Breaking the Efficacy Ceiling in IBD and Beyond
5